Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
COMPASS Pathways ( (CMPS) ) has shared an update.
On October 26, 2025, Compass Pathways announced the appointment of Dr. Jeffrey Jonas to its Board of Directors, effective October 29, 2025. Dr. Jonas, with over three decades of experience in pharmaceutical research and development, particularly in neuroscience, will also serve on the audit and risk and scientific committees. His extensive background in life sciences and leadership roles in various biopharmaceutical companies is expected to significantly benefit Compass Pathways as it advances its COMP360 program towards potential commercialization. As part of this transition, Thomas Lönngren will retire from the Board at the end of December 2025 after more than six years of service, during which he contributed to the company’s growth and strategic direction.
The most recent analyst rating on (CMPS) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on COMPASS Pathways stock, see the CMPS Stock Forecast page.
Spark’s Take on CMPS Stock
According to Spark, TipRanks’ AI Analyst, CMPS is a Neutral.
Compass Pathways demonstrates potential due to its strong equity position and progress in clinical trials. However, significant financial risks due to a lack of revenue and increasing operational costs weigh heavily on its performance. The stock’s upward momentum is promising, but valuation remains challenging due to negative profitability. The recent earnings call underscores both strategic progress and financial challenges, which tempers the overall outlook.
To see Spark’s full report on CMPS stock, click here.
More about COMPASS Pathways
Compass Pathways plc is a biotechnology company focused on accelerating patient access to evidence-based innovations in mental health. The company is pioneering a new paradigm for treating mental health conditions with its investigational COMP360 synthetic psilocybin treatment, which has received Breakthrough Therapy designation from the FDA and ILAP designation in the UK for treatment-resistant depression.
Average Trading Volume: 1,710,355
Technical Sentiment Signal: Buy
Current Market Cap: $613M
For a thorough assessment of CMPS stock, go to TipRanks’ Stock Analysis page.